AOCS is a national and international resource that researchers, with approved projects, can utilise for their research. Further information on how to apply for access to AOCS data or biospecimens can be found here.
Listed below are the details of projects that have been supported by AOCS to date.
| Project Number | Applicant’s Name | Affiliation | Title of Project |
| 05/3 | Ahmed Ashour Ahmed | Hutchinson/MRC Research Centre | Analysis of p53 mutation status of ovarian tumours |
| 05/6 | Adele Green | Queensland Institute of Medical Research (QIMR) | Quality of Life in Advanced Ovarian Cancer |
| 05/7 | Phyllis Butow | Director Medical Psychology Research Unit, University of Sydney | Quality of Life and psychosocial predictors of outcome in Ovarian Cancer |
| 05/8 | Richard Tothill | Peter MacCallum Cancer Centre | Expression profiling of mucinous tumours arising in the Ovary |
| 06/2 | Georgia Chenevix-Trench | Queensland Institute of Medical Research (QIMR) | Identification of low-risk susceptibility genes in the AOCS |
| 06/3 | Paul Pharoah | University of Cambridge – Strangeways Research Laboratory | A genome wide study to evaluate the association between germline genetic variation and disease risk in epithelial ovarian cancer |
| 06/4 | Phillippa O’Brien | Garvan Institute of Medical Research | Epigenetic markers of ovarian cancer |
| 06/5 | David Bowtell | Peter MacCallum Cancer Centre | Characterization of a cohort of AOCS women with a previous history of breast cancer |
| 06/6 | Alex Dobrovic | Peter MacCallum Cancer Centre | Validation of High Resolution Melting Analysis Using AOCS Samples |
| 06/7 | Robyn Ward | St. Vincents Hospital Sydney & University of New South Wales | The role of germline epimutations in ovarian cancer |
| 07/1 | David Bowtell | Peter MacCallum Cancer Centre | DoD – Project 1: Molecular Subtype Analysis of Ovarian Cancer |
| 07/2 | Penny Webb | Queensland Institute of Medical Research (QIMR) | DoD – Project 2 – Determinants of Epithelial Ovarian Cancer – by Histologic Subtype & Tumour Behaviour |
| 07/3 | Georgia Chenevix-Trench | Queensland Institute of Medical Research (QIMR) | DoD – Project 3 – Low Risk Genes for Epithelial Ovarian Cancer |
| 07/4 | Adele Green & Penny Webb | Queensland Institute of Medical Research (QIMR) | Comparison of quality of Life and Chemotherapy End-Points in Advanced Ovarian Cancer |
| 07/5 | Penny Webb | Queensland Institute of Medical Research (QIMR) | The Insulin-like growth factor system, lifestyle and risk and prognosis of ovarian cancer |
| 07/6 | Michelle Haber | Children’s Cancer Institute Australia for Medical Research | Prognostic significance of ABCC/MRP transporter gene expression in Ovarian Cancer |
| 07/7 | Penny Webb | Queensland Institute of Medical Research (QIMR) | Folate and related micronutrients, folate metabolising genes and risk of ovarian cancer |
| 07/8 | Debbie Handolias | Peter MacCallum Cancer Centre | Molecular analysis of the P13K pathway in ovarian cancer and correlation with clinical and pathological parameters |
| 07/9 | Paul Scuffham | Griffith University | Economic assessment of treatment in advanced ovarian cancer (pilot study) |
| 07/10 | Mike Anglesio | Peter MacCallum Cancer Centre | High Resolution Study of Ovarian Clear Cell Carcinoma |
| 07/11 | Gillian Mitchell | FCC, Peter MacCallum Cancer Centre | Genetic Profiling in the Australian Ovarian Cancer Study |
| 08/1 | Martin Oehler | Royal Adelaide Hospital | Profiling of the Immunoproteome in early ovarian cancer |
| 08/2 | Wayne Tilley | University of Adelaide / Hanson Institute | Androgen receptor activity in normal and abnormal human ovarian function |
| 08/3 | David Bowtell | Peter MacCallum Cancer Centre | Mutation scanning by deep sequencing of ovarian cancer |
| 08/4 | Joellen Schildkraut | Duke University Medical Centre | Comprehensive evaluation of DNA repair pathways in Ovarian Cancer |
| 08/5 | Debbie Handolias | Peter MacCallum Cancer Centre | Molecular analysis of the P13K pathway in ovarian cancer and correlation with clinical and pathological parameters |
| 08/6 | Georgia Chenevix-Trench | Queensland Institute of Medical Research (QIMR) | Response of Chemotherapy in Ovarian Cancer |
| 04/2 | Dariush Etemadmoghadam | Peter MacCallum Cancer Centre | SNP Based CGH analysis |
| 08/7 | Anna deFazio | Westmead Institute for Cancer Research – Westmead Millenium Institute | Chemosensitising pathways in Ovarian Cancer |
| 08/8 | Penny Webb | Queensland Institute of Medical Research (QIMR) | Pooled analyses of epidemiologic risk factors and gene x environment interactions for ovarian cancer |
| 08/9 | David Bowtell | Peter MacCallum Cancer Centre | Analysis of the Ovarian Cancer Genome by deep sequencing |
| 08/10 | David Bowtell | Peter MacCallum Cancer Centre | AOCS Participation in The Cancer Genome Atlas (TCGA) project |
| 08/11 | Maria Kavallaris | Children’s Cancer Institute Australia for Medical Research | Targeting the Cytoskeleton in Cancer |
| 08/12 | Anna deFazio | Westmead Institute for Cancer Research – Westmead Millennium Institute | Molecular Pathways from Low Malignant Potential to Invasive Ovarian Cancer |
| 08/13 | Prue Cowin | Peter MacCallum Cancer Centre | Genomic analysis of primary epithelial ovarian cancers and patient-matched relapse ascites |
| 08/14 | Keiran Harvey | Peter MacCallum Cancer Centre | Is the Salvador-Warts-Hippo Pathway deregulated in human cancer? |
| 08/15 | David Huntsman | British Columbia Cancer Agency | A Novel Marker for Granulosa Cell Tumours |
| 08/16 | Pritinder Kaur | Peter MacCallum Cancer Centre | Pericytes: Prognostic indicators of aggressive recurrent carcinomas and accelerated tumour growth |
| 08/17 | David Bowtell | Peter MacCallum Cancer Centre | Detection of alternatively spliced genes and fusion genes in ovarian cancer using whole genome exon array data |
| 08/18 | Frances Balkwill | Barts and The London Medical School | A study evaluating the predictive value of pro-inflammatory cytokine pathway enrichment for response to targeted therapy in epithelial ovarian cancer |
| 09/1 | Kylie Gorringe | Peter MacCallum Cancer Centre | Meta-analysis of Ovarian Cancer Copy Number data |
| 09/2 | Ian Campbell | Peter MacCallum Cancer Centre | High resolution genetic analysis of putative ovarian cancer precursors |
| 09/3 | Penny Webb | Queensland Institute of Medical Research (QIMR) | Ovarian Cancer Patterns of Care Survey |
| 09/4 | David Bowtell | Peter MacCallum Cancer Centre | Analysis of methylation status in primary serous ovarian cancer and patient matched relapse ascites. |
| 09/5 | Keith Dunker | Indiana University – Purdue University at Indianapolis | Gene Signature and Biomarker development in Cancer and Toxicogenomics |
| 09/6 | Penny Webb | Queensland Institute of Medical Research (QIMR) | Epidemiology of endometrial cancer |
| 09/7 | David Bowtell | Peter MacCallum Cancer Centre | Validation of Candidate Genes |
| 09/8 | Georgia Chenevix-Trench | Queensland Institute of Medical Research (QIMR) | Patterns of methylation in BRCA1, BRCA2 and sporadic ovarian cancer – a pilot study |
| 09/9 | Ian Campbell | Peter MacCallum Cancer Centre | Next Generation Sequencing of Ovarian Carcinoma |
| 09/10 | David Bowtell | Peter MacCallum Cancer Centre | Molecular Features of “BRCA-ness”: an extension of Project #07/11 – Genotyping in the Australian Ovarian Cancer Study |
| 09/11 | David Bowtell | Peter MacCallum Cancer Centre | Siah2 Protein Expression in Ovarian Cancer |
| 09/12 | Robert Bast | UT MD Anderson Cancer Centre | Early Detection of Ovarian Cancer: Autoantibodies against Mutant p53 |
| 09/13 | Gregory Rice | Baker IDI Heart & Diabetes Institute | Phase 2 Biomarker Study of multimarker ovarian cancer diagnostics |
| 09/14 | David Huntsman | British Columbia Cancer Agency | SWI/SNF Mutations in Clear Cell Carcinoma |
| 09/15 | David Bowtell | Peter MacCallum Cancer Centre | International Cancer Genomics Consortium Study |
| 10/01 | Jessica McAlpine | University of British Columbia. Academic Offices – Department of Gynaecology and Obstetrics. | HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy |
| 10/02 | Zhigang Wang / Ursula Matulonis | Departments of Medical Oncology & Cancer Biology, Dana-Farber Cancer Institute | Genetic relationships between breast and ovarian cancer: shared chromosomal alterations and response to chemotherapy |
| 10/03 | Vanessa Beesley | Queensland Institute of Medical Research (QIMR) | Quality of Life among women with platinum-resistant and platinum-sensitive ovarian cancer who were treated for recurrence: A Prospective Study |
| 10/04 | Aslaug Hellend | Oslo University Hospital, The Norwegian Radium Hospital | Copy Number changes in Serous Ovarian Carcinomas |
| 10/05 | Derek Richard | Queensland Institute of Medical Research (QIMR) | hSSB1 protein expression in ovarian cancer |
| 10/06 | Stuart McGregor | Queensland Statistical Genetics – Queensland Institute of Medical Research (QIMR) | Identifying markers of risk and outcome in ovarian cancer via efficient evaluation of DNA methylation in peripheral blood |
| 10/07 | Christopher Jones | UCL EGA Institute for Women’s Health | Accurate prediction of survival by aCGH analysis of ovarian tumours |
| 10/08 | Paul James | FCC, Peter MacCallum Cancer | A translational study to investigate the clinical significance of low penetrance breast cancer genes in a cohort of Victorian hereditary breast/ovarian cancer families |
| 10/09 | Madeleine King | University of Sydney, School of Psychology A18, Brennan MacCallum Building | Multi-Attribute Utility in Cancer (MAUCa): Development and valuation of cancer-specific multi-attribute health states for use in economic evaluation |
| 10/10 | William Foulkes | Department of Medical Genetics, McGill University Health Centre, Montreal General Hospital Site | Long Term Survivors of Advnaced Stage Heriditary Ovarian Cancer: Molecular clues into remarkable treatment outcomes |
| 10/11 | Stephen Chanock | Laboratory of Translational Genomics, Division of Cancer Genetics and Epidemiology, National Cancer Institute | Deep Sequencing of 19p13 |
| 10/12 | Paul Pharoah | Reader in Cancer Epidemiology, Departments of Oncology and Public Health and Primary Care, University of Cambridge | BRCA1/2 Germline Mutations and Ovarian Cancer Survival |
| 10/13 | Gillian Mitchell | FCC, Peter MacCallum Cancer Centre | Genetic Profiliing of the kConFab BRCAX cohort for selected breast cancer susceptibility loci and effect on cancer risk |
| 10/14 | Hannah Shipman | Cardiff University UK. Presently: Centre for Health & Society, Melbourne School of Population Health | Consent for novel techniques in clinical practice and genetic research: Current experiences and looking ahead |
| 10/15 | Andreas Obermair | Queensland Centre for Gynaecological Cancer | Development of an Australian Adnexal Mass Index (AMI) |
| 10/16 | Jonathan Beesley | Queensland Institute of Medical Research (QIMR) | Telomerase Gene Variation in Ovarian and Breast Cancer |
| 11/01 | Clare Scott | WEHI | Development of a Novel Xenograft Mouse Model of High Grade Epithelial Ovarian Cancer for Analysis of Therapeutic Manipulation in order to Improve Outcomes for Patients with Ovarian Cancer |
| 11/02 | Alex Dobrovic | Peter MacCallum Cancer Centre | Constitutional DNA methylation in blood and its role in ovarian cancer pathogenesis |
| 11/03 | Pam Pollock | IHBI, Queensland University of Technology | Exome resequencing, validation of hits in large population based cohorts and xenograft model development for serous endometrial cancer |
| 11/04 | Linda Mileshkin | Peter MacCallum Cancer Centre | Impact of obesity on ovarian cancer – a retrospective review on the effects of obesity on chemotherapy dosing, outcomes and survival in patients with ovarian cancer |
| 11/05 | Ian Campbell | Peter MacCallum Cancer Centre | Genetic Analysis of mucinous ovarian tumours |
| 11/06 | David Bowtell | Peter MacCallum Cancer Centre | Analysis of biomarkers in ovarian cancer through the OTTA consortium |
| 11/07 | Leonie Noon | University of Queensland (UQ) | Factors Influencing Uptake of Genetic Services |
| 11/08 | Fergus Couch | Mayo Clinic | Genetic modifiers of ovarian cancer in BRCA1 mutation carriers |
| 11/09 | Anna deFazio | Westmead Institute for Cancer Research, Uni of Sydney at Westmead Millennium Institute | Molecular pathways from low malignant potential to invasive ovarian cancer |
| 11/10 | Elizabeth Christie | Peter MacCallum Cancer Centre | Identification of circulating TP53 mutations as a biomarker of high grade serous cancer |
| 11/11 | Susan Ramus | University of Southern California; Department of Preventative Medicine, Harlyne Norris Tower | Next generation sequencing to identify moderate risk susceptibility genes for ovarian cancer |
| 12/01 | Deborah Marsh | Kolling Institute of Medial Research | Investigation of a putative marker of BRCAness and drug response in epithelial ovarian cancer |
| 12/02 | Goli Samimi | Garvan Institute of Medical Research | TLE3 as a biomarker for taxane sensitivity in ovarian cancer |
| 12/03 | Gillian Mitchell | FCC, Peter MacCallum Cancer Centre | Defining the hereditary contribution to ovarian cancer: the role of mismatch repair genes |
| 12/04 | Penny Webb | Queensland Institute of Medical Research (QIMR) | Vitamin D and survival from ovarian cancer |
| 12/05 | Heather Thorne | FCC, Peter MacCallum Cancer Centre | Investigating for the presence of a HOXB13 G84E germline variant in both familial breast and prostate cancer |
| 12/06 | Anna deFazio | Westmead Institute for Cancer Research | Molecular markers of relapse and treatment response in ovarian cancer |
| 12/07 | Alex Ng | Brigham and Women’s Hospital | Epigenetic silencing BRCA1 by C-terminal binding proteins in ovarian cancer |
| 13/01 | Orla McNally | Royal Women’s Hospital (VIC) | ER/PR Status in Ovarian Cancer |
| 13/02 | Huei-San Leong | Peter MacCallum Cancer Centre | Molecular Classifier Project |
| 13/03 | David Bowtell | Peter MacCallum Cancer Centre | Whole exome sequencing in ovarian cancer (ETHICS 09/38) |
| 13/04 | Jennifer Byrne | Kids Research Institute, University of Sydney | A novel mechanism for ATM inactivation-the role of TPD52 |
| 13/05 | FCC | Special requests to access GL for BRCA testing where all other avenues are closed | |
| 13/06 | Graham Taylor | University of Melbourne | Design and Analytical Validation of an Ovarian Cancer Mutation Panel |
| 13/07 | Elizabeth Christie | Peter MacCallum Cancer Centre | Identification of Circulating TP53 Mutations as a Biomarker of High Grade Serous Cancer |
| 13/08 | Rachel Turner | Roche Diagnostics | Australian Population Data for Avastin Submission to the PBAC |
| 13/09 | Christina Annunziata | National Cancer Institute, National Institutes of Health (NIH) | Correlation Studies of NFKB Cooperating Proteins Among Ovarian Cancer Subtypes |
| 13/10 | Mary-Anne Young | Peter MacCallum Cancer Centre | Informational and support needs of AOCS participants following notification of the availability of clinically significant genetic information |
| 14/01 | Anna deFazio | The Westmead Institute of Medical Research | APP1086390 Carboplatin hypersensitivity: a paradigm for exploring allergy pathogenesis |
| 14/02 | Anna deFazio | The Westmead Institute of Medical Research | APP1084587 Title: Disclosure of Individual Research Results and Incidental Findings from Translational Tissue Bank Genomic Research: Addressing the Clinical, Ethical- legal and Logistic Complexities |
| 14/03 | David Bowtell | Peter MacCallum Cancer Centre | AOCS and the MOCOG Consortium |
| 14/04 | Susan Ramus | University of Southern California | Contribution of Rare Alleles to Ovarian Cancer |
| 14/05 | Viola Heinzelmann-Schwartz | University Hospital Basel, Switzerland | Effect of beta blocker on the therapy of ovarian cancer – a retrospective data base analysis |
| 14/06 | Maree Bilandzic | MIMR-PHI Institute of Medical Research | Profiling the Molecular Signature of the Invasive Interface: Identifying Novel Targets to Combat Ovarian Cancer Metastasis |
| 14/07 | Penny Webb | QIMR Berghofer Medical Research Institute | Histological and molecular subtyping of ovarian cancer |
| 15/01 | Anna deFazio | The Westmead Institute of Medical Research | APP 1101576 Identifying Molecular Drivers in LGS Ovarian Cancer and Developing Therapeutic Strategies for Ras-pathway Activated Subtypes |
| 15/02 | Pritinder Kaur | Peter MacCallum Cancer Centre | NHMRC PROJECT GRANT APP1103065 Investigating interactions between ovarian cancer cells and the mesenchymal microenvironment underlying cancer progression |
| 15/03 | Judith Clements | Queensland University of Technology at the Translational Research Institute | NHMRC PROJECT GRANT APP1105922 Targeting kallikrein proteases to improve treatment options for ovarian cancer |
| 15/04 | Naisana Asli | Victor Chang Cardiac Research Institute NSW | NHMRC PROJECT GRANT APP1108938 A Novel Approach to Characterise and Target Ovarian Cancer Stem Cells |
| 15/05 | David Bowtell | Peter MacCallum Cancer Centre | Understanding chemotherapy resistance in ovarian cancer |
| 15/06 | Anna deFazio | The Westmead Institute of Medical Research | Carcinosarcoma of the ovary: clinical epidemiology, genomics and new treatment targets |
| 15/07 | Paul Hertzog | Hudson Institute of Medical Research | The Role of Novel Interferon Epsilon in Ovarian Cancer |
| 15/08 | Nikola Bowden | University of Newcastle | Investigation of Nucleotide Excision Repair Proteins as Biomarkers of Platinum Resistance for Ovarian Cancer |
| 15/09 | Tania Moujaber | The Westmead Institute of Medical Research | Molecular Pathways in Low-Grade Serous Ovarian Cancer |
| 16/01 | David Bowtell in collaboration with Prof George Coukos | University Hospital of Lausanne (CHUV) | Characterization of the immunogenicity of high-grade serous ovarian cancer (HGSC) |
| 16/02 | Caroline Ford | Lowy Cancer Research Centre, NSW | NHMRC PROJECT GRANT APP1123181 Silencing the ROR: New Targets In Ovarian Cancer |
| 16/04 | Judith Clements | Queensland University of Technology at the Translational Research Institute | Molecular Pathways Regulating Ovarian Cancer Cell Plasticity and Stem Cell Properties |
| 16/05 | Maiken Espersen | The Westmead Institute of Medical Research | Clinical proteomics and personalised treatment in ovarian cancer |
| 16/06 | Masataka Takenasa | Peter MacCallum Cancer Centre | Identification of the predictive biomarker of chemo-sensitivity in ovarian clear cell carcinoma |
| 16/08 | Anand Jeyasekharan | Cancer Science Institute of Singapore | Developing strategies to target CCNE1 amplified high grade serous ovarian cancer (HGSC) |
| 17/04 | Ali Freimund | Peter MacCallum Cancer Centre | Sub-Optimal Outcomes In BRCA Carriers: Identifying the determinants of treatment failure in ovarian cancer patients with a BRCA1 or BRCA2 germline mutation |
| 17/05 | Rachel Delahunty | Peter MacCallum Cancer Centre | TRACEBACK - identification of women carrying germline BRCA1/2 mutations through a retrospective analysis of patients diagnosed with high grade ovarian cancer |
| 17/07 | Brad Nelson | British Columbia Cancer Agency, Canada | Unleashing the immune response against T cell-poor ovarian cancers |
| 17/08 | Tracy Crane | University of Arizona, USA | Symptom profiles of women participating in the Australian Ovarian Cancer Study |
| 18/01 | George-Au-Yeung | Peter MacCallum Cancer Centre | BEACON - Targeting the C1 Subtype of High Grade Serous Ovarian Cancer |
| 18/02 | Yanina Natanzon | Dept of Health Sciences Research, Mayo Clinic, USA | Association between germline genetic variation and response to single-agent second-line chemotherapy in women with high-grade serous ovarian cancer |
| 18/03 | Frances Balkwill | Barts Cancer Institute, Queen Mary University of London | BEACON - Targeting the C1 Subtype of High Grade Serous Ovarian Cancer |
| 18/05 | Roshni Kalachand | Royal College of Surgeons, Dublin, Ireland | BRCA1 promoter methylation and clinical outcomes in epithelial ovarian |
| 18/06 | Susan Ramus | Molecular Oncology Group Lowy Cancer Research Centre, NSW | Identification of prognostic markers for ovarian cancer using DNA copy number and RNA expression |
| 19/01 | Carlos Salomon | UQ Centre for Clinical Research, QLD | Validation of a Novel Exosomal Biomarker Panel for the Detection of Ovarian Cancer – Liquid Biopsies to Monitor the Oncogenic Transformation of The Ovary |
| 19/02 | Yael Naaman | Royal Women’s Hospital, VIC | FoOTPrint Trial |
| 19/03 | Ling Shen | Venn Biosciences Corporation, CA, USA | Serum-based Circulating Glycoproteomic Biomarker Profiling of Ovarian Cancer |
| 19/04 | Lynne Postovit | Department of Oncology, University of Alberta, CANADA | Embryonic protein Nodal as a novel marker of progression and drug resistance of ovarian cancer |
| 19/05 | Ryan van Laar | Geneseq Biosciences, VIC | Technical And Clinical Utility Of Micro-Rna Signature In Ovarian Cancer Diagnosis |
| 19/06 | Rosemary Balleine | Children's Medical Research Institute (CMRI) | Proteomic Analysis of Cancer Tissues by SWATH-MS |
| 19/07 | Jurgen Piek | Catharina Cancer Institute, Netherlands | Signal Transduction Pathways in Ovarian Cancer |
| 19/09 | Penny Webb | QIMR Berghofer, QLD | Vitamin D and survival following a diagnosis of ovarian cancer – Amendment |
| 19/10 | Pawel Zawadzki | Adam Mickiewicz Universit, Poland | Molecular mechanisms of interplay between DNA repair pathways in chemotherapy resistance |